Nan Fung Trinity HK Ltd. Invests $16.74 Million in Bruker Corporation $BRKR

Nan Fung Trinity HK Ltd. bought a new position in Bruker Corporation (NASDAQ:BRKR) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 355,300 shares of the medical research company’s stock, valued at approximately $16,738,000. Bruker comprises 1.3% of Nan Fung Trinity HK Ltd.’s investment portfolio, making the stock its 29th largest position.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Sector Gamma AS lifted its stake in Bruker by 28.0% in the third quarter. Sector Gamma AS now owns 250,909 shares of the medical research company’s stock worth $8,152,000 after acquiring an additional 54,939 shares during the period. Becker Capital Management Inc. lifted its stake in Bruker by 606.8% in the third quarter. Becker Capital Management Inc. now owns 301,155 shares of the medical research company’s stock worth $9,800,000 after acquiring an additional 258,545 shares during the period. DNB Asset Management AS lifted its stake in Bruker by 40.5% in the third quarter. DNB Asset Management AS now owns 143,257 shares of the medical research company’s stock worth $4,654,000 after acquiring an additional 41,289 shares during the period. Aquatic Capital Management LLC lifted its stake in Bruker by 120.3% in the third quarter. Aquatic Capital Management LLC now owns 349,596 shares of the medical research company’s stock worth $11,358,000 after acquiring an additional 190,883 shares during the period. Finally, M&G PLC lifted its stake in Bruker by 233.0% in the third quarter. M&G PLC now owns 1,096,226 shares of the medical research company’s stock worth $35,079,000 after acquiring an additional 766,992 shares during the period. Institutional investors own 79.52% of the company’s stock.

Bruker Stock Performance

Shares of Bruker stock opened at $44.16 on Friday. The company has a current ratio of 1.55, a quick ratio of 0.87 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $6.72 billion, a P/E ratio of -184.00, a P/E/G ratio of 2.65 and a beta of 1.12. The business has a fifty day simple moving average of $37.26 and a two-hundred day simple moving average of $42.06. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $56.22.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.23 by $0.08. The business had revenue of $823.40 million during the quarter, compared to analyst estimates of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The company’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts forecast that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, March 23rd. This represents a $0.20 annualized dividend and a yield of 0.5%. Bruker’s dividend payout ratio (DPR) is currently -83.33%.

Analyst Ratings Changes

A number of analysts recently commented on BRKR shares. UBS Group raised their price target on Bruker from $40.00 to $45.00 and gave the stock a “neutral” rating in a research note on Thursday. Citigroup raised their price target on Bruker from $40.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday. Weiss Ratings raised Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, April 24th. Jefferies Financial Group set a $50.00 price target on Bruker in a research note on Thursday, February 12th. Finally, The Goldman Sachs Group dropped their price target on Bruker from $40.00 to $35.00 and set a “sell” rating for the company in a research note on Friday, February 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Bruker presently has a consensus rating of “Hold” and a consensus target price of $50.54.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the completion of the transaction, the vice president owned 128,443 shares of the company’s stock, valued at approximately $5,124,875.70. This trade represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 27.20% of the company’s stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.